Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer?
Rebecca S Heist, Geoffrey Liu and Wei Zhou*
Correspondence *Department of Epidemiology, Merck Research Laboratories, UG1D–60, PO Box 1000, North Wales, PA 19454, USA
Email wei_zhou2@merck.com
This article has no abstract so we have provided the first paragraph of the full text.
Although disease (tumor-node-metastasis) stage remains the primary predictor of survival in NSCLC, efforts are underway to identify molecular markers that improve prognostication, particularly within each disease stage.1, 2 Assessing immunofluorescence in tissue microarray samples collected from patients with NSCLC undergoing surgery between 1991 and 2001, Zheng et al. measured tumor protein levels of RRM1 (involved in DNA synthesis), and ERCC1 (a nucleotide excision DNA repair protein). Zheng et al. reported that among stage I NSCLC patients treated with surgical resection alone, patients with tumors that had both elevated RRM1 and ERCC1 expression had improved survival compared with patients whose tumors had high expression of one or neither protein.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.